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Background: Even after drug eluting stent (DES) implantation, the prognosis of diabetic patients are poorer than non-diabetics. Newly developed 
DES with biodegradable polymer is presumed to reduce late adverse events. However, the long-term safety and efficacy of those novel stents in 
treating diabetic patients were still unknow.
Methods: A total of 2077 patients, exclusively treated with biodegradable polymer based sirolimus eluting stents (Excel, JWMS, Weihai, China), 
were enrolled in the prospective, multicenter CREATE registry. 18-month clinical outcomes were compared between diabetic [440 (21.2%)] and non-
diabetic patients [1637 (78.8%)]. The primary events were defined as the composite of cardiac death, myocardial infarction (MI) or target vessel 
revascularization (TLR).
Results: Baseline clinical characteristics were comparable between diabetic and non-diabetic patients except that higher proportions of diabetic 
patients were complicated with hypertension (68.9% vs. 52.2%, p<0.001) and hyperlipidemia (23.6% vs. 15.9%, p<0.001). The mean stent number 
(1.92 ±1.2 vs. 1.77 ±1.1, p<0.01), stent length (22.6 ±5.5mm vs. 22.0 ±5.2mm, p<0.05) and stent diameter (3.01 ±0.43mm vs. 3.06 ±0.44mm, 
p<0.01) were significantly different between diabetic and non-diabetic patients. At 18-month follow-up, the rate of cumulative cardiac death was 
higher in diabetic patients compared with non-diabetic patients (2.5% vs.0.8%, p=0.001). However, the rates of primary events (3.4% vs.3.0%, 
p=0.199) and stent thrombosis (0.7% vs.0.9%, p=0.463) were similar between diabetic and non-diabetic patients. Angiographic follow-up at 
9-month showed that diabetic patients had a similar in-stent restenosis rate compared with non-diabetic patients (6.6% vs.6.7%, p=0.853).
Conclusions: The similar 18-month clinical outcomes between diabetic and non-diabetic patients in the present study demonstrate good safety 
and efficacy profiles of the novel biodegradable polymer based sirolimus eluting stent in treating diabetic patients. Those findings need confirmation 
by randomized trials.
